What are the options in HER2 postive breast cancer treatments are we moving to t-DXd in first line?
Hassan GHAZAL
oncologist, Dubai
oncologist, Dubai
New User? Click here to register
Text generated by AI based on an exclusive interview, revised and reviewed by
Foucauld CHAMMING’S
Luc Rotebenberg
Expert Opinions Dubai 2022
BCU General Secretary
Yazid BELKACEMI
Oncologist-Radiotherapist, Créteil, France
Copyright © 2026 - BCU